Share This Author
Effectiveness of whole-exome sequencing and costs of the traditional diagnostic trajectory in children with intellectual disability
The increased causal variant detection yield by WES and the relatively high costs of the entire traditional diagnostic trajectory suggest that early implementation of WES is a relevant and cost-efficient option in patient diagnostics.
Whole-exome sequencing in intellectual disability; cost before and after a diagnosis
- T. Vrijenhoek, Eline M Middelburg, G. Frederix
- MedicineEuropean Journal of Human Genetics
- 29 June 2018
Application of WES results in a considerable reduction of healthcare costs, not just in current settings, but even more so when applied earlier in the diagnostic trajectory (genetics-first), and WES may replace less cost-effective traditional technologies without compromising the diagnostic yield.
Utility and work productivity data for economic evaluation of breast cancer therapies in the Netherlands and Sweden.
Disease specific methods for economic evaluations of breast cancer therapies
- G. Frederix
- Medicine, Political Science
- 12 June 2013
Whether current model based CEAs in early breast cancer have sufficient quality, whether modelling methods are comparable between published articles and whether they reflect “real world” disease progression is studied.
The Impact of Structural Uncertainty on Cost-Effectiveness Models for Adjuvant Endocrine Breast Cancer Treatments: the Need for Disease-Specific Model Standardization and Improved Guidance
Differences in model structure and parameterization lead to substantial differences in analysis outcome metrics and supports the need for more guidance regarding structural uncertainty and the use of standardized disease-specific models for health economic analyses of adjuvant endocrine breast cancer therapies.
Reviewing the cost-effectiveness of endocrine early breast cancer therapies: influence of differences in modeling methods on outcomes.
Use of quality checklists and need for disease-specific guidance in economic evaluations: a meta-review
- G. Frederix, J. Severens, A. Hövels
- MedicineExpert review of pharmacoeconomics & outcomes…
- 4 July 2015
More international collaboration should be initiated in developing and publishing standardized and open source disease-specific reference models to overcome the problem of the wide variability of methodological choices prevalent in some other disease areas too, regardless of the availability of quality checklists.
The cloudy crystal ball of cost-effectiveness studies.
Real world cost of human epidermal receptor 2-positive metastatic breast cancer patients: a longitudinal incidence-based observational costing study in the Netherlands and Belgium.
- G. Frederix, J. Severens, J. Schellens
- Medicine, Political ScienceEuropean journal of cancer care
- 21 November 2014
Estimates of resource use and costs for HER-2-positive MBC in the Netherlands and Belgium show various differences in resource use patterns between both countries demonstrating caution is needed when transferring cost estimates between countries.
Micro-costing Diagnostics in Oncology: From Single-Gene Testing to Whole Genome Sequencing
Detailed cost differences and value comparisons between these diagnostic techniques enable future economic evaluations to support decision-making on implementation of WGS and other diagnostic modalities in routine clinical practice.